Module 1: NAFLD - Diagnosis and Identification of Those at Risk of Disease Progression
AASLD LiverLearning®, Mary Rinella, 175468
Module 2: Pathogenesis of Non-alcoholic Steatohepatitis
AASLD LiverLearning®, Arun Sanyal, 175469
Module 9: Emerging Treatments for Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, Stephen A. Harrison, 175470
Non-Alcoholic Fatty Liver Disease & Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, AASLD, 175471
Module 6: Bariatric Surgery: Is the Cure for NASH in the OR?
AASLD LiverLearning®, Philippe MATHURIN, 175078
Module 4: Lifestyle Interventions: Setting Goals and Recommendations
AASLD LiverLearning®, Brent Tetri, 175077
Module 3: Non-Invasive Determination of Advanced Disease in NAFLD
AASLD LiverLearning®, Leon Adams, 174314
Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 170278
Summary of the Meeting: What to Do Next?
AASLD LiverLearning®, Keith Lindor, 170277
Emerging Therapy for NASH: Antifibrotics
AASLD LiverLearning®, Scott Friedman, 169510
Emerging Therapy for NASH: Non-antifibrotics
AASLD LiverLearning®, Stephen Harrison, 169509
The Current Medical Treatment for Patients with NASH
AASLD LiverLearning®, Manal Abdelmalek, 169508
Weight Loss and Exercise in NAFLD
AASLD LiverLearning®, Jacob George, 169507
What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
AASLD LiverLearning®, Kris Kowdley, 169506
Serum Fibrosis Markers in NASH
AASLD LiverLearning®, Quentin Mark Anstee, 169505
Noninvasive Biomarkers in NASH
AASLD LiverLearning®, Naga Chalasani, 169504
Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
AASLD LiverLearning®, Zachary Goodman, 169502
The comparative effect of liraglutide, elafibranor and obeticholic acid on NAFLD Activity Score and Fibrosis Stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
AASLD LiverLearning®, Michael Feigh, 170270
VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease
AASLD LiverLearning®, Patrick Colin, 170269
Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Monica Konerman, 170268
Predicting the degree of liver-biopsy-confirmes steatosis and fibrosis using transient elastography and magnetic resonance imaging-based techniques in adult patients with suspected non-alcoholic fatty liver disease
AASLD LiverLearning®, Stephen Harrison, 170267
The Association of Histologic Activity with Long Term Outcomes of Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Maria Stepanova, 170266
Steatosis, Portal Inflammation and Fibrosis are More Advanced in Younger Children with Non-Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Reham Abdou, 170265
NASH and Bariatric Surgery
AASLD LiverLearning®, Philippe MATHURIN, 169500
Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
AASLD LiverLearning®, Joel Lavine, 169499
Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Arun Sanyal, 169498
Fibrogenesis of NASH: What Is Different About It?
AASLD LiverLearning®, Scott Friedman, 169496
NAFLD and Microbiome
AASLD LiverLearning®, Kathleen Corey, 169495
The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
AASLD LiverLearning®, Stephen Caldwell, 169493
Session II: Metabolic Syndrome and NASH : Q&A
AASLD LiverLearning®, Session Speakers, 170256
Cardiovascular Diseases and NAFLD
AASLD LiverLearning®, Francesco Negro, 169492
Lipid Abnormalities in NAFLD
AASLD LiverLearning®, lawrence serfaty, 169491
Insulin Resistance in NAFLD
AASLD LiverLearning®, Brent Tetri, 169490
Is MS the Consequence or Precursor of NASH?
AASLD LiverLearning®, Giulio Marchesini, 169489
Q&A
AASLD LiverLearning®, Session Speakers, 169830
Will the Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
AASLD LiverLearning®, Elisabetta Bugianesi, 169488
Long Term Outcomes: Mortality and Causes of Death in NAFLD
AASLD LiverLearning®, Mary Rinella, 169487
Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
AASLD LiverLearning®, Zobair Younossi, 169486
Welcome and Opening Remarks
AASLD LiverLearning®, Zobair Younossi, 169828
Welcome and Opening Remarks
AASLD LiverLearning®, Keith Lindor, 169829
Controversy Regarding HCV Treatment and HCC Recurrence
AASLD LiverLearning®, Amit Singal, 167450
Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Daniel Antoine, 171991
The role of the hepatopathologist in the assessment of drug‐induced liver injury
AASLD LiverLearning®, David Kleiner, 171992
Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Michael Trauner, 171993
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
AASLD LiverLearning®, Eamonn M. M. Quigley, 171994
Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines
AASLD LiverLearning®, Jasmohan S. Bajaj, 171995
Overview of causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Paul Hayashi, 171996
Portal Vein Thrombosis in Cirrhosis: Causes and Consequences
AASLD LiverLearning®, Stephen Caldwell and Juan C. Garcia-Pagan, 167449
Thrombosis and coagulopathy in the liver transplant candidate and recipient
AASLD LiverLearning®, R. Todd Stravitz, 169134
The highly sensitized, high MELD, simultaneous liver‐kidney or status 1A heart‐liver transplant candidate
AASLD LiverLearning®, Timucin Taner, 169135
Genetics in liver diseases: From diagnostics to precise therapy
AASLD LiverLearning®, Frank Lammert, 169136
Developing a liver cancer program in the nonacademic medical center
AASLD LiverLearning®, Kent Benner, 169137
Changes in united network for organ sharing policy for simultaneous liver‐kidney allocation
AASLD LiverLearning®, David Mulligan, 169138
Elastography to assess the stage of liver fibrosis in children: Concepts, opportunities, and challenges
AASLD LiverLearning®, Claude Sirlin, 169139
Module 5: Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
AASLD LiverLearning®, Kathleen Corey, 166911
Module 8: Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Dawn Torres, 166127
Module 7: Managing NASH Cirrhosis and Assessment for Liver Transplant
AASLD LiverLearning®, Kymberly Watt, 173365
A framework to determine when liver transplantation is futile
AASLD LiverLearning®, Jennifer Lai, 165947
The changing face of hepatic encephalopathy: A projection for the next 5 years
AASLD LiverLearning®, Debbie L Shawcross, 165948
Treatment of chronic cholestasis: What we know and what we will know?
AASLD LiverLearning®, James Boyer, 165949
Managing encephalopathy in the outpatient setting
AASLD LiverLearning®, Radha Dhiman, 165950
Mechanisms of portal hypertension: Bench to bedside
AASLD LiverLearning®, Jordi Gracia‐Sancho, 165951
Novel approaches to the treatment of biliary atresia
AASLD LiverLearning®, Jorge A. Bezerra, 165952
Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Pietro Invernizzi, 164849
How does the microbiome affect liver disease?
AASLD LiverLearning®, Herbert Tilg, 164850
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
AASLD LiverLearning®, Ali Canbay, 164851
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853
Cystic Fibrosis–Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology
AASLD LiverLearning®, Mario Strazzabosco, 164854
Clinical Hepatology Debrief
AASLD LiverLearning®, Arun Sanyal, 154738
Elimination of Hepatitis B: Is It possible?
AASLD LiverLearning®, Anna Lok, 154737
Hepatitis Debrief
AASLD LiverLearning®, Robert Brown, 154735
Pangenotypic Regimens and the Next Generation of HCV Treatment
AASLD LiverLearning®, Nancy Reau, 154728
Resistance Testing: Interpretation and Incorporation into Treatment Algorithms
AASLD LiverLearning®, Jordan Feld, 154727
Management of Acute Variceal Bleed
AASLD LiverLearning®, Shiv Kumar Sarin, 154734
Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®, Jason Grebely, 154726
Non-cirrhotic Portal Hypertension: Eastern Perspective
AASLD LiverLearning®, Hitoshi Maruyama, 154733
In memoriam: Maribel Rodrigez Torres
AASLD LiverLearning®, Norbert Brau, 155710
HCV Symposium: Challenges in the DAA Era: Program Chair
AASLD LiverLearning®, Norah Terrault, 154723
Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®, David Roth, 154725
TIPS: Is Early Intervention Helpful?
AASLD LiverLearning®, Florence Wong, 154732
Non-cirrhotic Portal Hypertension: Western Perspective
AASLD LiverLearning®, Theo Heller, 154731
AASLD-APASL Symposium: Portal Hypertension: Program Chair
AASLD LiverLearning®, Rajender Reddy, 154729
New Treatments for NASH
AASLD LiverLearning®, Brent Tetri, 154722
Advances in Non-invasive Assessment and Genetics of NAFLD
AASLD LiverLearning®, Christopher Paul Day, 154721
Advances in the Management of Alcoholic Liver Disease
AASLD LiverLearning®, Philippe MATHURIN, 154720
Early Hospital Readmissions and Mortality in Patients with Decompensated Cirrhosis enrolled in a Large National Health Insurance Administrative Database
AASLD LiverLearning®, Steven Scaglione, 144641
A Creatinine-Modified Child-Turcotte-Pugh (CTP-Cr) outperforms the original CTP and Model for End Stage Liver Disease (MELD) for predicting short- and long-term transplant-free survival in a national cohort with cirrhosis.
AASLD LiverLearning®, David Kaplan, 144657
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Immunity in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144673
Serum Ceruloplasmin can be applied to assess liver fibrosis in chronic hepatitis B virus patients with normal or minimally raised ALT
AASLD LiverLearning®, Da-Wu Zeng, 144689
The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections
AASLD LiverLearning®, Florian van Boemmel, 144706
Profiling Changes in Neutrophil-Lymphocyte Ratio in Response to Antiviral Therapy for Chronic Hepatitis B Infection
AASLD LiverLearning®, Marnonette Marallag, 144722
Comparison of the efficacy of entecavir and tenofovir monotherapy for the treatment of treatment -naïve patients with hepatitis B virus
AASLD LiverLearning®, Young Kul Jung, 144738
High Frequency of Flares in Alanine Aminotransferase (ALT) And Hepatitis B Virus (HBV) DNA During Pregnancy And Postpartum in Women With Chronic Hepatitis B (CHB) Who Discontinued Therapy Prior to or During Early Pregnancy
AASLD LiverLearning®, Christine Chang, 144754
Clinical features and long term outcomes of Autoimmune hepatitis (AIH) and its overlap with Primary Sclerosing Cholangitis (PSC)
AASLD LiverLearning®, Guan Wee Wong, 144545
Oncostatin M plays a crucial role in liver fibrogenesis by regulating cooperation between hepatic stellate cells and macrophages
AASLD LiverLearning®, Michitaka Matsuda, 144561
Phenotype of human intrahepatic innate lymphoid cell subsets in health and disease
AASLD LiverLearning®, Ye Htun Oo, 144577
LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis
AASLD LiverLearning®, Suriguga S, 144593
Attention to “Cirrhosis” in the News Media in 36 Countries Worldwide: Insufficient Awareness of Non-alcoholic Compared to Alcoholic Liver Disease.
AASLD LiverLearning®, Nambi Ndugga, 144609
Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer
AASLD LiverLearning®, Sara Miller, 144625